Closing meeting of the project with the members of the LiquiDx consortium

On September 18, 2025, the LiquiDx consortium held the closing face-to-face meeting of the project at the facilities of the Biobank of the Public Health System of Andalusia (BBSSPA), in Granada. The sessions, which were also broadcast via videoconference, made it possible to review the progress made in the development of an RNA-based liquid biopsy tool for the early detection of five types of cancer of great clinical relevance: lung, colon, breast, prostate and pancreas. During the meeting, experiences and learnings were shared around the quality requirements of plasma samples, as well as strategies to mitigate batch effects in the discovery of biomarkers. The day concluded with the analysis of the steps necessary for the preparation of the final technical report and with a guided tour of the BBSSPA facilities. 

The LiquiDx project represents a significant advance in the innovation of cfRNA-based liquid biopsies, by integrating next-generation sequencing technologies, bioinformatics, and sequencing solutions. precision medicine with the aim of creating a cutting-edge diagnostic platform applicable in clinical settings. This progress underscores the consortium's strong commitment to early cancer detection and accelerating the transfer of new technologies to accessible clinical tools that help improve patient outcomes. it is expected that the main results obtained will be disseminated to the scientific community through a specialized publication. 

Flomics Biotech, Leitat and the BBSSPA would like to express their appreciation for the financial support received for the execution of the LiquiDx project, associated with file CPP2021-008897 and financed by the MCIN/AEI/10.13039/501100011033, as well as by the European Union, through the "NextGenerationEU/PRTR" funds and the 2021 call for public-private collaboration projects of the State Research Agency.